Altamira Therapeutics Ltd... (CYTO)
Altamira Therapeutics Statistics
Share Statistics
Altamira Therapeutics has 3.78M shares outstanding. The number of shares has increased by 68.67% in one year.
| Shares Outstanding | 3.78M |
| Shares Change (YoY) | 68.67% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 3.13% |
| Shares Floating | 2.65M |
| Failed to Deliver (FTD) Shares | 7.89K |
| FTD / Avg. Volume | 5.59% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.2 and the forward PE ratio is null. Altamira Therapeutics's PEG ratio is 0.
| PE Ratio | -0.2 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 0.22 |
| P/FCF Ratio | -0.12 |
| PEG Ratio | 0 |
Enterprise Valuation
Altamira Therapeutics has an Enterprise Value (EV) of 918.84K.
| EV / Sales | 0 |
| EV / EBITDA | -0.68 |
| EV / EBIT | -0.08 |
| EV / FCF | -0.08 |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.38 |
| Quick Ratio | 1.38 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.07 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -112.56% and Return on Invested Capital is -85.68%.
| Return on Equity | -112.56% |
| Return on Assets | -94.49% |
| Return on Invested Capital | -85.68% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-727K |
| Employee Count | 10 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -78.57% in the last 52 weeks. The beta is 2.44, so Altamira Therapeutics's price volatility has been higher than the market average.
| Beta | 2.44 |
| 52-Week Price Change | -78.57% |
| 50-Day Moving Average | 0.23 |
| 200-Day Moving Average | 0.81 |
| Relative Strength Index (RSI) | 46.38 |
| Average Volume (20 Days) | 141.04K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -5.92M |
| Net Income | -7.27M |
| EBITDA | -1.35M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -14.81 |
Balance Sheet
The company has 617.41K in cash and 99.66K in debt, giving a net cash position of 517.75K.
| Cash & Cash Equivalents | 617.41K |
| Total Debt | 99.66K |
| Net Cash | 517.75K |
| Retained Earnings | -18.05M |
| Total Assets | 7.69M |
| Working Capital | 334.24K |
Cash Flow
In the last 12 months, operating cash flow was -11.51M and capital expenditures 0, giving a free cash flow of -11.51M.
| Operating Cash Flow | -11.51M |
| Capital Expenditures | 0 |
| Free Cash Flow | -11.51M |
| FCF Per Share | -23.44 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CYTO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -506.06% |
| FCF Yield | -801.28% |
Analyst Forecast
Currently there are no analyst rating for CYTO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Dec 13, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Dec 13, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -3.85 |
| Piotroski F-Score | 3 |